NEWS & EVENTS

 

F-star enters into strategic collaboration to develop bispecific antibodies in immuno-oncology

 
F-star enters into strategic collaboration to develop bispecific antibodies in immuno-oncology

10 July 2017

F-star, a biopharmaceutical company developing bispecific antibody immuno-oncology products, has announced a new partnership with a leading science and technology company. This new strategic collaboration will focus on the development and commercialisation of five bispecific immuno-oncology antibodies, including F-star’s preclinical lead asset FS118. The deal, potentially worth over €1 billion, will also see F-star receive up to €115 million in upfront, R&D funding and milestone payments in the first two years. This collaboration will support their mission to transform the treatment of cancer.

Read the full press release here.

Mewburn Ellis partner Tanis Keirstead and patent assistant Sean Constable work with F-star in relation to their IP portfolio.